K-Pio-Gm Tablet ER is a combination oral hypoglycemic agent formulated for the management of type 2 diabetes mellitus. It contains Glimepiride 2 mg, Metformin 500 mg, and Pioglitazone 15 mg, each contributing distinct mechanisms to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, enhancing glucose uptake by muscle tissues. Pioglitazone, a thiazolidinedione, acts as an insulin sensitizer by activating peroxisome proliferator-activated receptor gamma (PPAR-γ), which modulates gene expression involved in glucose and lipid metabolism. The extended-release (ER) formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency. K-Pio-Gm Tablet ER is indicated for patients inadequately controlled on monotherapy or dual therapy, providing a comprehensive approach to glycemic management. It should be used under medical supervision with regular monitoring of blood glucose, renal and hepatic function. Caution is advised in patients with heart failure, hepatic impairment, or risk factors for lactic acidosis. Adverse effects may include hypoglycemia, gastrointestinal disturbances, weight gain, and edema. This combination therapy offers a synergistic effect to improve glycemic parameters and reduce the risk of diabetes-related complications.